Katherine E Talcott
Overview
Explore the profile of Katherine E Talcott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanna J, Markle J, Maatouk C, Das N, Talcott K, Singh R
Ophthalmic Surg Lasers Imaging Retina
. 2025 Mar;
:1-6.
PMID: 40085093
Background And Objective: This study aimed to analyze baseline predictors of visual response in patients with neovascular age-related macular degeneration (nAMD) who have undergone lapses in treatment with anti-VEGF therapy....
2.
Abbass N, Nahlawi R, Shaia J, Allan K, Kaelber D, Talcott K, et al.
Am J Ophthalmol
. 2025 Feb;
PMID: 40015592
Purpose: The association between GLP-1 receptor agonists (GLP-1RA) and non-arteritic anterior ischemic optic neuropathy (NAION) remains unclear. Given the debilitating sequelae of NAION and rapid increase of GLP-1RA use, further...
3.
Abbass N, Shaia J, Shukla P, Cohen D, Kaelber D, Talcott K, et al.
Eye (Lond)
. 2025 Feb;
PMID: 40011738
Background/objectives: Data on the prevalence of optic neuritis (ON) is limited with reported rates between 5.5 and 115.3 per 100,000. The US data is even more limited with the largest...
4.
Shaia J, Rock J, Chu J, Trinh I, Alam T, Singh R, et al.
J Neuroophthalmol
. 2025 Feb;
PMID: 39930564
Background: Fulminant idiopathic intracranial hypertension (IIH) is a rare presentation of IIH characterized by rapid visual loss. Little is known regarding the cause of fulminant IIH and how to treat...
5.
Bala S, Barbosa G, Mohan N, Srivastava S, Kaiser P, Sastry A, et al.
Ophthalmol Retina
. 2025 Feb;
PMID: 39923899
Purpose: To evaluate the short-term outcomes of patients with exudative neovascular age-related macular degeneration (nAMD) treated with high-dose aflibercept 8.0 mg (HDA), focusing on anatomical and functional changes, as well...
6.
7.
Allan K, Joo J, Kim S, Shaia J, Kaelber D, Singh R, et al.
Ophthalmology
. 2025 Jan;
PMID: 39863057
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have risen exponentially in usage and have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigates whether GLP-1RAs...
8.
Szigiato A, Maatouk C, Azar A, Alsaloum P, Talcott K, Singh R, et al.
J Vitreoretin Dis
. 2025 Jan;
:24741264241305107.
PMID: 39742141
To evaluate the prevalence of geographic atrophy (GA) lesions in patients with a diagnosis of intermediate age-related macular degeneration (iAMD). A retrospective cross-sectional study was performed of patients with an...
9.
Rana N, Chalasani M, Markle J, Russell M, Li A, Talcott K, et al.
J Vitreoretin Dis
. 2024 Dec;
:24741264241304813.
PMID: 39678939
To evaluate the effect of antivascular endothelial growth factor (anti-VEGF) agents on the development of sustained intraocular pressure (IOP) elevations. This single-center retrospective cohort study included eyes receiving anti-VEGF injections...
10.
Chalasani M, Maatouk C, Markle J, Singh R, Talcott K
J Vitreoretin Dis
. 2024 Dec;
:24741264241305123.
PMID: 39678936
To identify baseline characteristics that predict visual outcomes after a lapse in treatment among patients with diabetic macular edema (DME) who received intravitreal antivascular endothelial growth factor injections. In this...